Kiniksa Pharmaceuticals International, plc
KNSA
$47.02
$0.521.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.95% | 61.17% | 44.34% | 72.54% | 46.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.95% | 61.17% | 44.34% | 72.54% | 46.93% |
| Cost of Revenue | 37.66% | 69.10% | 67.76% | 96.46% | 149.16% |
| Gross Profit | 96.90% | 54.93% | 29.39% | 57.05% | -0.74% |
| SG&A Expenses | 40.06% | 5.83% | 10.54% | 12.53% | 10.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.57% | 28.69% | 25.65% | 29.16% | 70.24% |
| Operating Income | 202.43% | 348.72% | 17,330.77% | 180.23% | -23,925.93% |
| Income Before Tax | 237.05% | 477.13% | 892.93% | 209.03% | -793.02% |
| Income Tax Expenses | 212.10% | 58.81% | -18.79% | 104.96% | 64.49% |
| Earnings from Continuing Operations | 259.75% | 245.24% | 556.29% | 148.23% | -135.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 259.75% | 245.24% | 556.29% | 148.23% | -135.22% |
| EBIT | 202.43% | 348.72% | 17,330.77% | 180.23% | -23,925.93% |
| EBITDA | 207.07% | 363.58% | 6,455.27% | 184.70% | -3,143.32% |
| EPS Basic | 252.07% | 239.38% | 541.45% | 146.89% | -134.27% |
| Normalized Basic EPS | 230.47% | 462.36% | 859.11% | 206.02% | -772.94% |
| EPS Diluted | 246.70% | 227.78% | 483.33% | 143.89% | -134.96% |
| Normalized Diluted EPS | 221.13% | 438.28% | 803.45% | 201.19% | -795.26% |
| Average Basic Shares Outstanding | 5.07% | 4.17% | 3.43% | 2.85% | 2.77% |
| Average Diluted Shares Outstanding | 13.16% | 11.58% | 9.77% | 7.80% | -0.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |